Civic News
Environment / Health tech

Delaware Money Moves: AstraZeneca’s $2.4B deal for cancer-fighting drug

Plus, chemical water technologies manufacturer Solenis acquired two cleaning companies, Lilleborg and Aqua ChemPacs.

Solenis Headquarters in Avenuue North. (Technical.ly/Holly Quinn)
Money Moves is a feature where we chart the raises, mergers and other funding news of tech companies across the region on the third Wednesday of the month. Have a tip? Email us at delaware@technical.ly.

Delaware is heading into summer with big deals in some of the state’s biggest industries. 

Global Chemtech company Solenis is on a roll with sustainable cleaning, while AstraZeneca keeps growing in the precision medicine space.

Also, the Port of Wilmington back on track, Big Fish expands outside of the small pond and One Custom House gets a buyer.

Get all the details below the chart, our monthly look at which companies are hiring for tech jobs in the Delaware market, and how that’s changed since last month.

Solenis leans into green cleaning with two acquisitions

Wilmington-based chemical water technologies manufacturer Solenis has acquired the Norwegian company Lilleborg, makers of chemical cleaning products for the food and beverage industry. Solenis acquired 100% of the company for an undisclosed amount.

This acquisition came just days after Solenis announced its acquisition of Aqua ChemPacs, a Pennsylvania company that makes professional cleaning pods that dissolve in water. Solenis launched in 2014, but evolved from companies spanning back over 100 years, including Hercules and Drew Chemical.

AstraZeneca makes $2.4 billion deal for precision cancer drug

AstraZeneca, the British/Swedish global pharmaceutical firm with a longtime US base in Wilmington, acquired California-based Fusion Pharmaceuticals for $2.4 billion. The precision medicine company developed FPI-226, a drug that combines radioactive treatment with a targeting agent that seeks out cancerous cells. The drug is a potential new treatment for prostate cancer.

This AstraZeneca deal follows a $1 billion winter acquisition of cell therapy firm Gracell Biotechnologies.

Check out more Delaware Money Moves:

Companies: Solenis / AstraZeneca
Series: Money Moves

Before you go...

Please consider supporting Technical.ly to keep our independent journalism strong. Unlike most business-focused media outlets, we don’t have a paywall. Instead, we count on your personal and organizational support.

3 ways to support our work:
  • Contribute to the Journalism Fund. Charitable giving ensures our information remains free and accessible for residents to discover workforce programs and entrepreneurship pathways. This includes philanthropic grants and individual tax-deductible donations from readers like you.
  • Use our Preferred Partners. Our directory of vetted providers offers high-quality recommendations for services our readers need, and each referral supports our journalism.
  • Use our services. If you need entrepreneurs and tech leaders to buy your services, are seeking technologists to hire or want more professionals to know about your ecosystem, Technical.ly has the biggest and most engaged audience in the mid-Atlantic. We help companies tell their stories and answer big questions to meet and serve our community.
The journalism fund Preferred partners Our services
Engagement

Join our growing Slack community

Join 5,000 tech professionals and entrepreneurs in our community Slack today!

Trending

The Trump rally shooter perched on a building owned by American Glass Research. Here’s everything we know about it.

Quantum computing could be the next hot tech — if only that breakthrough would come

Here’s how the global tech outage impacted many of the vital systems across the mid-Atlantic region

5 Delaware startups fighting the climate crisis

Technically Media